Peter Noymer, PhD

Peter Noymer, PhD, joined Kedalion Therapeutics in 2017 as President and CEO, leading a team advancing novel therapies for topical ocular delivery using the proprietary AcuStream platform. Prior to Kedalion, Peter was Chief Operating Officer at SteadyMed, responsible for the development and scale-up of a cardiovascular therapy based on a novel, prefilled, wearable infusion system that received Orphan Drug Designation from the FDA. Earlier, he served as VP of Product R&D at Alexza Pharmaceuticals, obtaining FDA and EMA approval for Adasuve®, the first inhalable treatment for acute agitation. Peter also served in management roles at Aradigm Corporation, taught at Carnegie Mellon University and held engineering positions at GE. Dr. Noymer received MS and PhD degrees from MIT, and a BS degree from Princeton University.